Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Ovarian Neoplasms 12Breast Neoplasms 9Fallopian Tube Neoplasms 6Carcinoma, Ovarian Epithelial 5Squamous Cell Carcinoma of Head and Neck 4Endometrial Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Non Small Cell Lung Carcinoma NSCLC 2Neoplasms, Unknown Primary 2Neoplasms 2NSCLC 2Melanoma 2Esophageal Neoplasms 2Adenocarcinoma 2Urologic Neoplasms 1Urogenital Neoplasms 1Unresectable Stage III NSCLC 1Triple Negative Metastatic Breast Cancer 1Thyroid Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcopenia 1

Interventions

Pemetrexed 1Immune Checkpoint Inhibitors 1Drug Therapy 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
First-line Advanced NSCLC Patients × CP protocol × Clear all
NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 2 Recruiting
240 enrolled
Thoracic

First-line Advanced NSCLC Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡